Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET

Company Participants

Anthony Bergmann - CFO

Linda Marbán - President and CEO

Conference Call Participants

Joe Pantginis - H.C. Wainwright

Operator

Good day and welcome to the Capricor Therapeutics' Second Quarter 2022 Earnings Call. Today's conference is being recorded.

At this time, I would like to turn the conference over to Mr. A.J. Bergmann, CFO. Please go ahead, sir.

Anthony Bergmann

Thank you and good afternoon. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our product candidates, our future R&D plans, including our anticipated conduct and timing of preclinical and clinical studies; our plans to present or report additional data; our plans regarding regulatory filings, potential regulatory developments involving our product candidates, potential milestone payments; and our possible uses of existing cash and investment resources.

These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.

These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements and we disclaim any obligation to update such statements.

With that, I'll turn the call over to Linda Marbán, CEO.

Linda Marbán

Good afternoon and thank you for joining us for our second quarter 2022 conference call. Today I will provide updates on our Duchenne muscular dystrophy program and our exosome platform technology, as well as outline our priorities and path forward. This quarter has been productive on many fronts and most notably, we achieved several key milestones across our lead program, CAP-1002 for the treatment of Duchenne muscular dystrophy, otherwise known as DMD.

To remind you, our current clinical initiative is aimed at treating DMD patients who are largely non-ambulant and in the later stages of their disease, and of course, for whom very few therapeutic options exist.

This patient group comprises about half of the DMD population or about 10,000 boys and young men in the United States. We've completed two successful clinical trials in DMD and CAP-1002 has proven to be safe and well-tolerated in over 200 patients to-date.